DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for nasopharyngitis — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNasopharyngitis maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for nasopharyngitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
KH RNA binding domain containing, signal transduction associated 3 (KHDRBS3) — KHDRBS3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5EMO · 3.03 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
A 2020 article on silver proteinate for acute nasopharyngitis describes the condition as common, benign, and self-limited, with high complication rates in children. The authors note that many drugs lack evidence-based effectiveness. They present silver proteinate as a topical agent with broad antibacterial and anti-inflammatory activity, available in a new formulation with long shelf life. The article states the drug is effective and safe for use at any age, but provides no numerical data on response rates, symptom duration, or sample sizes. No controlled trial results are reported.
Two 2024 clinical case reports describe the use of Euphorbium compositum Nasentropfen S® and Engystol® as complex therapy for acute nasopharyngitis. Both state that a positive effect was achieved and that bioregulatory therapy allowed quick recovery. Neither report gives patient numbers, comparator groups, or quantitative outcomes such as time to symptom resolution. The evidence consists of single-case observations.
Across all three abstracts, no randomised controlled trials, no survival or response rate data, and no sample sizes are provided. The silver proteinate article claims high efficacy without supporting numbers. The two case reports offer no controlled data. What is missing are adequately powered randomised trials with objective outcome measures, transparent patient stratification by age and severity, and funding for independent comparative studies against placebo or standard care.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Meditsinskiy sovet = Medical Council · 2020 · 3 citations · open access
The efficacy of silver proteinate in the treatment of acute nasopharyngitis
AbstractAcute nasopharyngitis is the most common reason for visit a doctor, usually benign, self-limited disease. It is also characterized by a high frequency of complications in children and nonspecific symptoms that require special care from the doctor when examining patients. The clinical and social significance of acute nasopharyngitis is due to their high prevalence, and inadequate treatment leads to a protracted course or to a transition to a chronic one. The relevance of this problem adds to the presence of a large number of various drugs, but not many drugs have evidence-based effectiveness. In the treatment of acute nasopharyngitis local drugs are very important. The drug is a silver proteinate agent with broad antibacterial anti-inflammatory activity. The drug is used to treat infectious rhinitis. This article evaluates the use of a new form of the silver proteinatedrug, the drug is available in the pharmacy, easy to use, long shelf life. This article describes the place of silver proteinate among drugs that help to relieve the symptoms of acute nasopharyngitis and provides data on its effectiveness, safety and features of use in children. The drug can take a worthy place among topical drugs due to its high efficiency in the treatment of acute rhinitis and its possible use at any age.
Lekarstvennye sredstva i racionalʹnaâ farmakoterapiâ. · 2024 · 0 citations
THE USE OF EUPHORBIUM COMPOSITUM NASENTROPFEN S® AND ENGYSTOL® AS COMPLEX THERAPY FOR ACUTE NASOPHARYNGITIS
AbstractIn the clinical case under consideration, a positive effect was achieved in the treatment of acute nasopharyngitis through the use of complex therapy with the drugs Euphorbium compositum Nasentropfen S® and Engystol®. The use of bioregulatory therapy allows the patient to recover quickly.
Lekarstvennye sredstva i racionalʹnaâ farmakoterapiâ. · 2024 · 0 citations
BIOREGULATORY APPROACH TO COMPLEX THERAPY OF ACUTE RESPIRATORY DISEASE
AbstractIn the clinical case under consideration, a positive effect was achieved in the treatment of acute nasopharyngitis through the use of complex therapy with the drugs Euphorbium compositum Nasentropfen S® and Engystol®. Therapy using bioregulatory drugs allows you to effectively and quickly help the patient.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
